[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab, a fully human monoclonal antibody that blocks the interleukin-4 and interleukin-13 pathways, is approved for the treatment of five diseases marked by type 2 inflammation that are often ...

Dupilumab, a fully human monoclonal antibody, 19,20 blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. 18,21,22 Dupilumab is ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

No antibodies to dupilumab were detected in any other patients. Adverse event incidence ranged from 73% to 100% across the study groups and parts. Most were mild or moderate.

Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to ...

It contains lab-made proteins that work just like parts of your immune system called antibodies. Dupilumab targets two specific cytokines — interleukin-4 (IL-4) and interleukin-13 (IL-13 ...

This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. The data supporting the use of dupilumab in COPD will be reviewed by the United States Food and Drug ...

A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo.